Tresiba Cost in District of Columbia 2026

What Is Tresiba and Why Does It Matter for DC Patients?

Insulin degludec (brand name Tresiba, Novo Nordisk) is an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours. That profile allows flexible dosing: patients can shift their injection time by up to 8 hours day to day without meaningful glycemic disruption. For the approximately 55,700 adults in the District of Columbia estimated to have diagnosed diabetes (about 9.1% of DC adults, per CDC surveillance data), finding an affordable basal insulin is a practical daily concern. [1]

The DEVOTE trial (N=7,637, NEJM 2017) compared insulin degludec to insulin glargine U-100 in high-cardiovascular-risk type 2 diabetes patients over roughly 2 years. Degludec was non-inferior to glargine for major adverse cardiovascular events (MACE) and produced 40% fewer severe hypoglycemic episodes (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001). [2] That hypoglycemia advantage is clinically meaningful for DC patients who commute, drive, or work physically demanding jobs.

The FDA approved Tresiba in September 2015 for adults and in 2019 extended the label to include pediatric patients aged 1 year and older. [3] Both the U-100 (100 units/mL) and U-200 (200 units/mL) concentrations are available as FlexTouch pens.

Tresiba List Price vs. What DC Patients Actually Pay

The manufacturer's wholesale acquisition cost runs close to $510 per month for a standard supply. That number appears on many pharmacy sticker receipts and frightens patients away from filling their prescription. The real out-of-pocket figure is almost always lower.

Cash-pay price at DC pharmacies. Applying a GoodRx or RxSaver coupon at CVS, Walgreens, Giant Food Pharmacy, or Costco in the District of Columbia brings the average price to approximately $35 per month for a 30-day supply of Tresiba U-100 FlexTouch (5 pens, 300 units each). Prices fluctuate by pharmacy and by exact pack size, so patients should run real-time comparisons on GoodRx.com before presenting at the counter.

Novo Nordisk My$99Insulin program. Novo Nordisk caps Tresiba at $99 per month for uninsured or underinsured US patients through its My$99Insulin program. Patients apply directly at NovoCare.com. No income verification is required for the $99 cap. [4]

Insulin Cost-Sharing Cap (ACA/IRA provision). Under the Inflation Reduction Act provisions affecting Medicare Part D, insulin cost sharing is capped at $35 per fill for Medicare enrollees. DC residents on Medicare Part D pay no more than $35 per month for any covered insulin, including Tresiba if it sits on the plan's formulary. [5]

The table below summarizes the four main cost tiers a DC patient encounters:

| Payment pathway | Approximate monthly cost | |---|---| | Uninsured, no coupon (list price) | ~$510 | | Cash-pay with GoodRx/RxSaver coupon | ~$35 | | Novo Nordisk My$99Insulin (uninsured) | $99 | | Medicare Part D (IRA cap) | $35 | | DC Medicaid (after PA approval) | $0 copay for most enrollees | | Compounded insulin degludec (503A, eligible patients) | $0 to ~$50 |

DC Medicaid Coverage for Tresiba: Prior Authorization Requirements

DC Medicaid covers Tresiba for both type 1 and type 2 diabetes. Coverage is not automatic. Prescribers must submit a prior authorization (PA) request demonstrating that the patient has a clinical reason to use degludec rather than a preferred formulary basal insulin (typically insulin glargine biosimilars such as Semglee or Rezvoglar, which carry lower acquisition costs for the DC Medicaid program).

Common PA approval criteria include:

• Documented hypoglycemia on a preferred formulary basal insulin, or
• Clinician attestation that the flexible dosing window (the up-to-8-hour dose-timing variability) is medically necessary for the patient's work schedule or lifestyle, or
• Allergy or intolerance to glargine or detemir formulations.

The DC Department of Health Care Finance (DHCF) administers the DC Medicaid pharmacy benefit through managed care organizations including AmeriHealth Caritas DC, MedStar Family Choice DC, and Trusted Health Plan. PA criteria can vary slightly between plans, so the prescriber's office should verify the specific form required for the enrollee's plan before submitting.

Once approved, most DC Medicaid enrollees pay $0 or a nominal $1 to $3 copay per fill under the DC Medicaid cost-sharing schedule. PA approvals typically run for 12 months before renewal. [6]

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 1 or type 2 diabetes requiring basal insulin, selection should be individualized based on hypoglycemia risk, dosing schedule flexibility, cost, and patient preference." [7] That language directly supports PA appeals when a prescriber argues that degludec's flexible dosing window is medically necessary.

Is Compounded Insulin Degludec Legal in the District of Columbia?

Yes. Licensed 503A compounding pharmacies operating in the District of Columbia may legally compound insulin degludec preparations under Section 503A of the Federal Food, Drug, and Cosmetic Act, provided they compound for an individual patient with a valid prescription and do not produce large sterile batches intended for resale. [8]

503A vs. 503B distinction matters here. A 503A pharmacy compounds patient-specific prescriptions in smaller quantities; a 503B outsourcing facility may produce larger sterile batches for hospitals and clinics without patient-specific prescriptions. Most direct-to-patient telehealth pharmacies operating in DC are 503A registrants.

Cost of compounded insulin degludec varies but can be significantly below brand-name pricing, and some telehealth providers bundle the cost into their monthly membership fee, effectively bringing the patient's out-of-pocket cost to $0 after the subscription is factored in.

Key compliance points patients and prescribers should keep in mind:

1. The compounding pharmacy must hold a valid DC Board of Pharmacy license (or a home-state license if shipping into DC, subject to reciprocity rules).
2. The prescription must be patient-specific, with a legitimate prescriber-patient relationship established.
3. Compounded insulin degludec is not FDA-approved and does not carry the same labeling, stability testing, or post-market surveillance as branded Tresiba. Patients should discuss this with their prescriber before switching.

The FDA's guidance on compounded drug products notes that 503A pharmacies may not compound a product that is "essentially a copy" of a commercially available product unless there is a documented clinical difference. Prescribers should note any clinical rationale (such as a specific concentration, preservative-free formulation, or combined preparation) to support the compound's legitimacy. [8]

Telehealth Prescribing of Tresiba in DC: What the Rules Allow

Telehealth prescribing of Tresiba is legal in the District of Columbia. DC has maintained its expanded telehealth prescribing standards from the public health emergency period. A licensed physician, nurse practitioner, or physician assistant with a valid DC prescribing license may initiate or refill an insulin degludec prescription after a synchronous audio-video visit or, in some cases, an asynchronous evaluation if the platform and clinical circumstances meet DC Board of Medicine standards. [9]

Practically, this means a DC resident can:

• Schedule a video visit with an endocrinologist or telehealth platform (including HealthRX-affiliated prescribers) without leaving home.
• Receive a Tresiba prescription sent electronically to a local DC pharmacy or a mail-order pharmacy.
• Have compounded insulin degludec shipped to a DC address from a licensed 503A pharmacy following a valid telehealth visit.

Controlled-substance prescribing via telehealth remains subject to DEA rules, but insulin is not a controlled substance, so no DEA special registration is needed for insulin telehealth prescribing in DC.

Patients should confirm that the telehealth platform's prescribing clinician holds an active DC license. The DC Board of Medicine license lookup tool is publicly available at doh.dc.gov.

Insurance Coverage for Tresiba in DC: Commercial Plans

Commercial insurance coverage for Tresiba in the District of Columbia depends on the specific formulary. DC residents obtain commercial coverage through the DC Health Link exchange (which uses ACA Marketplace plans), employer-sponsored insurance, or individual plans. Common formulary placements include:

Tier 3 or Tier 4 (preferred or non-preferred brand). Most ACA and employer plans place Tresiba on a mid-to-high tier, with typical cost sharing of $40 to $80 per fill under standard deductible-applied pricing. Once the annual deductible is met, copays drop to the tier rate.

Step therapy requirements. Several DC commercial plans require patients to demonstrate failure or intolerance on a biosimilar glargine before approving Tresiba. Patients or prescribers may file a step-therapy exception if clinical documentation supports immediate degludec use.

Novo Nordisk NovoCare Savings Card. Commercially insured patients (not Medicare or Medicaid) may use the Novo Nordisk savings card to pay as little as $10 per fill for Tresiba. The card is available at NovoCare.com. Monthly fill limits and annual maximums apply; the 2026 card caps savings at $150 per 30-day supply and $1,800 per calendar year. [4]

The Kaiser Family Foundation analysis of DC insurance markets shows that the District's ACA Marketplace enrollment reached approximately 25,000 individuals in 2024, a figure that has grown each year since the ACA's inception. [10] Many of those enrollees carry plans where Tresiba's net cost after a savings card is under $20 per fill.

Comparing Tresiba to Formulary Alternatives in DC

Several basal insulins compete with Tresiba on DC pharmacy shelves and formularies in 2026:

Insulin glargine U-100 (Lantus, Semglee, Rezvoglar, Basaglar). Glargine biosimilars are the default preferred basal insulin on most DC Medicaid and commercial formularies. Cash-pay prices for Semglee (the FDA-interchangeable biosimilar) run near $20 to $30 per month with coupons. Tresiba's clinical advantage over glargine is its lower severe hypoglycemia rate (DEVOTE: 40% fewer severe hypoglycemic episodes) and flexible dosing window. [2]

Insulin detemir (Levemir). Novo Nordisk has announced plans to discontinue Levemir in the US; supply has become limited. Patients on detemir should discuss transitioning to degludec or glargine with their prescriber.

Toujeo (insulin glargine U-300). Toujeo offers a slightly longer effective duration than glargine U-100 and a smaller injection volume due to concentration. Some patients prefer it for reduced injection-site reactions. The BRIGHT trial (N=929) found comparable A1c reductions between degludec U-100 and glargine U-300 at 24 weeks, with degludec showing numerically fewer nocturnal hypoglycemic events. [11]

When formulary alternatives are inadequate or carry unacceptable hypoglycemia risk, the DEVOTE data and ADA 2024 Standards provide solid PA appeal language for prescribers seeking Tresiba authorization on DC Medicaid or commercial plans.

Novo Nordisk Patient Assistance and DC-Specific Programs

NovoCare Patient Assistance Program (PAP). DC residents who are uninsured and meet income eligibility (typically household income at or below 400% of the federal poverty level) may qualify for free Tresiba through the NovoCare PAP. Applications are submitted at NovoCare.com or by calling 1-800-727-6500. Processing takes approximately 2 to 4 weeks, and approved patients receive a 90-day supply at a time. [4]

DC Pharmaceutical Assistance Program. The DC Department of Health runs the DC Pharmaceutical Assistance Program (DC PAP) for DC residents aged 18 to 64 who lack drug coverage and meet income criteria. DC PAP may cover Tresiba for enrolled patients. Contact DC DHCF at 202-724-7700 for current formulary status. [6]

Hospital financial assistance. Georgetown University Hospital, MedStar Georgetown, GWU Hospital, and Howard University Hospital all operate financial assistance (charity care) programs that can include outpatient pharmacy support. DC residents presenting with insulin cost hardship should contact those programs' social work departments directly.

340B pricing. Federally Qualified Health Centers (FQHCs) and safety-net clinics in DC that participate in the 340B Drug Pricing Program can purchase Tresiba at a steep discount and pass those savings to low-income patients. Unity Health Care, Mary's Center, and La Clinica del Pueblo are major 340B-eligible providers in DC. Patients seen at 340B sites may access Tresiba at sharply reduced cost regardless of insurance status.

Clinical Profile: Dosing, Starting Doses, and Titration in DC Practice

Tresiba is dosed once daily at any time of day, with the caveat that consecutive injections must be at least 8 hours apart. The FDA-approved starting doses are: [3]

• Insulin-naive type 2 diabetes: 10 units once daily, then titrate.
• Switching from another basal insulin (type 2): Unit-for-unit conversion from the prior basal dose, then titrate.
• Type 1 diabetes: Approximately 60% to 70% of the total daily insulin dose as Tresiba, with the remainder as a rapid-acting insulin at meals.

The standard titration target for most adults is a fasting blood glucose of 80 to 130 mg/dL (per ADA 2024 glycemic targets). Dose increases of 2 units every 3 days are a common starting titration schedule, adjusted based on fasting glucose logs. [7]

Tresiba U-200 delivers 200 units per mL, so the pen dial shows units rather than mL. Patients switching from U-100 pens must use the U-200 pen without dose conversion: 20 units on the U-200 dial delivers 20 units of degludec regardless of concentration.

In older adults and patients with renal impairment (eGFR <30 mL/min/1.73m²), insulin requirements may decrease. Close glucose monitoring during dose transitions is standard practice.

Practical Steps for a DC Patient Starting or Continuing Tresiba in 2026

1. Get a current prescription. A DC-licensed prescriber (via in-person or telehealth visit) must write the Rx. Specify U-100 or U-200 and the number of pens per fill.
2. Check your formulary. Log into your DC Health Link, employer plan, or DC Medicaid portal and search for "insulin degludec" or "Tresiba" to see your tier and PA requirements before filling.
3. Apply a coupon or savings card. If commercially insured, use the Novo Nordisk NovoCare savings card. If uninsured, run a GoodRx search for the lowest DC pharmacy price.
4. Submit a PA if required. Your prescriber's office handles PA paperwork. Provide DEVOTE trial data and ADA 2024 Standards language to support medical necessity.
5. Ask about 340B sites. If you are uninsured or underinsured, ask whether your DC clinic participates in 340B. Unity Health Care has 20+ DC locations.
6. Consider compounding. If cost remains prohibitive and your prescriber identifies a clinical rationale, ask about a licensed 503A compounding pharmacy. Confirm the pharmacy's DC Board of Pharmacy license first.